Ekso Bionics® Launches Ekso GT with Smart Assist
04 October 2016 - 10:01PM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced it recently has shipped the first device
incorporating SmartAssist, its next generation gait therapy
software, allowing the company to expand the range of patients who
can participate in robotic therapy.
The SmartAssist technology, which is currently
available for Ekso GT devices in Europe, offers new options to
therapists for customizing training in gait and balance. The
SmartAssist software allows physical therapists to vary the support
of the device for each leg independently - from full power to free
walking - and thereby meet the specific needs of patients.
This capability enables the Ekso GT to rehabilitate a larger range
of patients, from those too weak to walk to those who are nearly
independent.
“SmartAssist has definitely made a change to how
we use the exoskeleton and broadened the spectrum of conditions we
can use it for,” commented Louis Martinelli, Neurological
Physiotherapist at Hobbs Rehabilitation in Winchester, England.
“The therapists can now adjust the settings to vary the support we
give, not only to the swing phase but the stance phase of gait,
giving the participant access to an optimal walking pattern.”
The Ekso GT with SmartAssist is a comprehensive
gait therapy tool that can support a broad spectrum of
patients. The technology allows patients to be more actively
engaged in their rehabilitation than ever before, enabling more
activity with higher intensity than previously possible.
“Ekso GT with SmartAssist software was developed
to expand the applications for use within clinics. The
addition of pre-gait exercises have facilitated earlier mobility
for some patients who could not have otherwise been mobile and our
new FreeGait advanced mode can help patients progress to community
ambulation,” commented Thomas Looby, chief executive officer of
Ekso Bionics. “We are excited to offer this as another life
changing solution for patients who use our exoskeletons for
rehabilitation.”
The SmartAssist software is not yet available in
the United States.
About Ekso Bionics® Ekso Bionics is a leading
developer of exoskeleton solutions that amplify human potential by
supporting or enhancing strength, endurance and mobility across
medical, industrial and defense applications. Founded in 2005, the
company continues to build upon its unparalleled expertise to
design some of the most cutting-edge, innovative wearable robots
available on the market. Ekso Bionics is the only exoskeleton
company to offer technologies that range from helping those with
paralysis to stand up and walk, to enhancing human capabilities on
job sites across the globe, to providing research for the
advancement of R&D projects intended to benefit U.S. defense
capabilities. The company is headquartered in the Bay Area and is
listed on the Nasdaq Capital Market under the symbol EKSO. For more
information, visit: www.eksobionics.com.
About Ekso™ GT
Ekso™ GT is the first
FDA cleared exoskeleton cleared for use with stroke
and spinal cord injuries from L5 to C7. The Ekso GT with
smart Variable Assist™ (marketed as SmartAssist outside the U.S.)
software is the only exoskeleton available for rehabilitation
institutions that can provide adaptive amounts of power to either
side of the patient’s body, challenging the patient as they
progress through their continuum of care. The suit’s patented
technology provides the ability to mobilize patients earlier, more
frequently and with a greater number of high intensity steps. To
date, this device has helped patients take more than 55 million
steps in over 120 rehabilitation institutions around the world.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the plans and objectives of management for future operations,
including plans or objectives relating to the design, development
and commercialization of human exoskeletons, (ii) a projection of
financial results, financial condition, capital expenditures,
capital structure or other financial items, (iii) the Company's
future financial performance and (iv) the assumptions underlying or
relating to any statement described in points (i), (ii) or (iii)
above. Such forward-looking statements are not meant to predict or
guarantee actual results, performance, events or circumstances and
may not be realized because they are based upon the Company's
current projections, plans, objectives, beliefs, expectations,
estimates and assumptions and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control over. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
adequate financing to fund the Company's operations and necessary
to develop or enhance our technology, the significant length of
time and resources associated with the development of the Company's
products, the Company's failure to achieve broad market acceptance
of the Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us
at www.eksobionics.com. The Company does not undertake to
update these forward-looking statements.
Media Contact:
Carrie Yamond/Rajni Dhanjani
212-867-1788
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024